Pancreatic beta-cell function is usually assessed by the measurement of plasma insulin concentration in various clinical situations. However, the advent of an assay for the measurement of connecting-peptide (C-peptide) concentration in plasma has provided a further method for the assessment of the secretory capacity of the pancreatic beta cell in clinical disorders, particularly in the investigation of hypoglycaemia. The metabolism and immunoassay methodology of C-peptide are reviewed, and its application in clinical practice is outlined.
Biosynthesis and degradation of insulin and C-peptide BIOSYNTHESIS Although it was thought originally that the two peptide chains of the insulin molecule were synthesised separately and were then coupled at a postribosomal site, it is now evident that biosynthesis takes place from a single-chain precursor molecule, prcinsulin.l P Human proinsulin (Fig. 1 ) is a polypeptide containing 86 amino-acid residues in which the N-terminal of the insulin A-chain is linked with the C-terminal of the B-chain via a connecting segment which consists of 35 amino acids." The connecting segment is thought to play an important role in the synthesis of insulin by ensuring the correct pairing of the cysteine residues during the formation of interchain disulphide bonds, thus facilitating the formation of the correct secondary and tertiary structures of insulin." Studies with isolated islets of Langerhans have shown that proinsulin is synthesised by ribosomes associated with the rough endoplasmic reticulum" and then transferred by an energy-dependent process to the Golgi apparatus," Proinsulin is then incorporated within the beta-cell granules and cleaved by proteolytic enzymes as the granules mature and migrate towards the plasma membrane of the pancreatic beta cell. 7 -1O Cleavage results in the loss of a pair of basic amino acids from each end of the connecting segment. The remainder of the connecting segment, known as C-peptide ( Fig. 1 ), is retained within the granules and released in equimolar quantities with insulin during emiocytosis. DEGRADATION Although equimolar concentrations of insulin and C-peptide are present in portal blood during peak pancreatic beta-cell secretion," the molar concentration of C-peptide in the peripheral circulation is higher than that of insulin (Table) . This may be explained in two ways. Firstly, studies in the rat have shown that the metabolic clearance rate of C-peptide (4' 6 mi/rnin) is considerably slower than that of insulin (16, 4 rnl/rnin), giving metabolic half-lives of 11·1 min and 4· 8 min, respectively.P Comparable observations have been made in man, although the reported values for the metabolic half-life of C-peptide do vary from 11'1 to 33· 5 min, depending on the conditions of study.I3-15 Secondly, while C-peptide is metabolised principally in the kidney, renal extraction accounting for approximately 69 %of the total metabolic clearance," insulin is removed rapidly from the portal circulation by the liver,1a-ls renal extraction accounting for only 33 % of the total clearance.P Concentrations of insulin and C-peptide, which are typical of those found in peripheral plasma in different situations, are shown in the Table. The molar ratio ofC-peptide to insulin is greatest in the fasting state but falls in non-steady state conditions, which occur after the ingestion of glucose or a meal.
Radioimmunoassay of C-peptide
Since C-peptide has no apparent biological activity, radioimmunoassay is the only analytical technique
Concentration of insulin and C-peptide in peripheral plasma of non-diabetic individuals

Sampling conditions
Insulin (nmol/f)
Fasting (n=23) 0·OS±0·02 0·47±0·19 60 min after SOII oral glucose (n~13) 0·33±0·13 1·9S±0·S2 10 min after O· S g/kg iv glucose (n = 6) 0·31±0·14 1·32±0·46 30 min after mixed meal [n ee l l ] 0·S2±O·03 1·76±0·08
Ashby mid Prier currently available for its determination. Because of the extensive species difference in both the number and sequence of amino acids in C-peptide,19 a separate assay utilising the appropriate purified peptide for standard, radioactive label, and antigen for the production of antibodies is required for the assay of C-peptide from each species. The early development of an assay for human C-peptide was hindered by problems of purification of the human peptide in adequate quantities. The assay has become available more widely, however, following the successful chemical synthesis of human Cpeptide by several groups of investigators, 20--22 especially since reagents can now be obtained commercially. In the UK the assay is now available for clinical purposes through the Supra-Regional Assay Service.
PRODUCTION OF C-PEPTIDE ANTISERA
Despite the species difference in the amino-acid sequence of C-peptide, the molecule generally shows low immunogenicity. This may be a consequence of its low molecular weight (3021 daltons for human C-peptide) and its lack of rigid secondary and tertiary structure. 23-24 Assays have been developed using antisera raised by immunising guinea-pigs with either crude b-component of pancreatic extract obtained by gel filtration of the first crystals of human insulin'" or a mixture of human proinsulin and its intermediate forms which have been separated from a crude extract of human insulin." The majority of laboratories, however, now use antibodies raised against the synthetic peptide. These can be prepared by injecting guinea-pigs with synthetic benzyloxycarbonyl human C-peptide coupled to albumins" or immunising rabbits with the synthetic connecting segment of human proinsulin."
RADIOACTIVE TRACER
Labelling of C-peptide with 125 1 is complicated by the absence of tyrosine residues from the peptide chain. It is, therefore, necessary to add this amino acid to the natural or the synthetic molecule before iodination by the method of Hunter and Greenwood'" as modified by Freychet et al. 29 C-PEPTIDE STANDARD Because of the difficulty in purifying natural human C-peptide most investigators use standards of synthetic C-peptide in their assay systems. In these circumstances it is necessary to confirm the immunological identity of the natural C-peptide and the synthetic standard. For example, it has been demonstrated that the relative immunoreactivity of synthetic and natural standard varies with the particular antiserum used.P' Furthermore, synthetic preparations of human C-peptide prepared by different methods may also behave differently in some assay systems. 22 STABILITY OF C-PEPTIDE IN PLASMA C-peptide immunoreactivity in plasma samples declines considerably with time,3O depending upon both the storage temperature and the antiserum used for assay." C-peptide immunoreactivity generally appears to be most stable when plasma is stored at -25°C, but a significant decay may still be observed under these conditions with some antisera" It is possible that this reflects the differing crossreactivity of antisera with C-peptide fragments formed during the in-vitro degradation of the parent molecule.P' It must, therefore, be stressed that the stability of plasma C-peptide immunoreactivity should be determined for each assay system.
INTERFERENCES
There are still many problems associated with the immunoassay of C-peptide. For example, the reported values for C-peptide immunoreactivity in healthy individuals vary considerably, fasting concentrations ranging from 0·9 to 3·5 ng/ml (0'30 to 1·16 nmol/l).112632 Plasma from long-standing insulin-treated diabetic subjects give zero values with some antisera but not with others," 27 suggesting that some antisera can react to a varying degree with substances other than C-peptide and proinsulin.
All antisera to C-peptide cross-react with proinsulin. The extent of this interaction depends on the method used to raise the antibody; the lowest reactivity (approximately 10% at best) is found using antisera raised against synthetic C-peptide. Antibodies raised against the connecting segment have a higher reactivity, while the greatest crossreaction is found using antisera raised against proinsulin itself.31 Since the molar concentration of proinsulin in fasting plasma is only about 5 % of that of C-peptide,33 values of C-peptide obtained using an antibody with low cross-reactivity (approximately 10 %) to proinsulin may be taken as representative of the true C-peptide concentration. However, if an antibody of poor specificity for C-peptide is used it is necessary to remove proinsulin from the sample before the assay of C-peptide.
Particular problems have been encountered in the measurement of C-peptide in the plasma of patients with insulin-dependent diabetes who have circulating insulin antibodies as a result of treatment with conventional insulin. These antibodies bind both exogenous and endogenous insulin and also proinsulin. Although proinsulin is quantitatively unimportant in normal subjects, antibody-bound proinsulin in these patients can exceed the concentration of circulating C-peptide. 34 In this situation it is mandatory to remove proinsulin from the samples before the assay of C-peptide since interference will occur with all C-peptide antisera that are currently available.
Separation of C-peptide from proinsulin can be accomplished by two methods: 1 Bound proinsulin and insulin are released by extraction of plasma with acid ethanol at pH = 2,0. 35 After drying down the ethanol extract and reconstituting in buffer, proinsulin may be removed from solution by binding with anti-insulin serum coupled to sepharose. C-peptide may then be determined in the supernatant.P 2 Polyethylene glycol may be used to remove antibody complexes before the concentration of free hormones or peptides in the supernatant is determined. 36
Clinical applications
Although the measurement of circulating C-peptide has contributed greatly to comprehension of the natural history and pathophysiology of insulindependent diabetess? and to the investigation of possible insulin feedback mechanisms during hypoglycaemia in normal man,98 39 the clinical applications of C-peptide measurement are limited. These are directed primarily to the investigation of hypoglycaemic disorders.
INVESTIGATION OF HYPOGLYCAEMIA
The investigation of spontaneous hypoglycaemia can present diagnostic difficulties unless the cause is clinically evident, such as advanced liver disease or adrenal insufficiency. When an insulin-secreting neoplasm is suspected, investigation traditionally has included the effect of a prolonged fast on plasma glucose and insulin concentrations, which may have been supplemented by tests using substances which stimulate insulin release, such as tolbutamide, leucine or glucagon. These stimulation tests using insulin secretagogues are unsatisfactory, giving both false-positive and false-negative results.s? and the tolbutamide test is now considered to be dangerous. While these stimulation tests generally are not used nowadays in the investigation of hypoglycaemia, a calcium/glucose infusion test has been described by Frerichs and Creutzfeldv which can detect inappropriate release of insulin secondary to a defect in the secretory control mechanism, and this test is abnormal in patients with insulinomas.
Autonomous endocrine secretion is more readily diagnosed by tests that suppress hormone secretion. Endogenous insulin secretion is suppressed in normal subjects during hypoglycaemia induced by alcoholv or by fish insulirr'" which does not cross-react with the antisera used for the assay of human insulin. Failure of suppression of insulin secretion has been reported in patients with insulinomas during hypoglycaemia induced by these methods," 43 but there are practical problems with both techniques. Fish insulin is not available for routine use, while infusion of alcohol does not induce reliable or marked hypoglycaemia and must be preceded by a 36-hour fast.
Inhibition of pancreatic beta-cell secretion during hypoglycaemia induced with conventional beef or pork insulins has been demonstrated by a fall in plasma C-peptide concentration, the suppression of which is prolonged until after the blood glucose has returned to normal.44 45 The C-peptide suppression test is a simple and reliable method for the investigation of spontaneous hypoglycaemia, which can be performed on an outpatient basis, thus obviating the need for time-consuming inpatient investigation. Insulin can be administered by intramuscular injection or by intravenous infusion, but, in our experience, the simplest and most reproducible method is to administer monocomponent shortacting insulin (0'15 units/kg body weight) by an intravenous bolus injection." The insulin is given after an overnight fast, with serial measurements of plasma glucose and C-peptide concentrations before and at 3D-minute intervals after insulin administration, up to 150 minutes (Fig. 2) . Plasma for C-peptide measurement should be separated within 30 minutes of collection of blood samples and stored deep frozen (-20°C).
Ashby and Frier
Impaired suppression of C-peptide secretion during insulin-induced hypoglycaemia indicates autonomous secretion of insulin. This has been demmonstrated in patients with proven insulinomas.w 47 and the C-peptide suppression test therefore provides a reliable method for the identification of an insulinsecreting tumour as a cause of spontaneous hypoglycaemia. This test, however, is not always diagnostic: occasional patients with insulinomas have normal C-peptide suppression," and failure of C-peptide suppression after insulin administration has been reported in a patient with pancreatic islet hyperplasia which was confirmed at necropsy. 48 These instances are rare, however, and this suppression test has provided a major advance in the diagnosis of insulin-secreting tumours.
The simultaneous measurement of plasma insulin and C-peptide concentrations during an episode of hypoglycaemia can distinguish between true spontaneous hypoglycaemia and factitious hypoglycaemia produced by self-administration of insulin. In pancreatic hyperinsulinism, plasma concentrations of insulin and C-peptide are elevated simultaneously during hypo glycaemia, because of their dual release from the pancreatic beta cells, whereas in hypoglycaemia an elevated plasma insulin concentration is associated with a low plasma Cpeptide. 4 9-51 Thus the simultaneous demonstration of low plasma concentrations of glucose and C-peptide with high concentrations of insulin is pathognomonic of exogenous administration of insulin.
In patients with insulin-dependent diabetes, in whom plasma insulin concentrations are difficult to interpret (because of cross-reactivity of human insulin with exogenous insulin and the presence of insulin antibodies), the estimation of C-peptide may be valuable to document the presence of endogenous hyperinsulinisrn.P as insulinomas do occur in diabetic subjects 53 54 although the true incidence is unknown. 41 However the diagnosis of factitious hypoglycaemia in patients with insulin-dependent diabetes with residual beta-cell function may be difficult, because insulin antibodies can bind with endogenous proinsulin and retard its metabolic clearance from the circulation.v Most assays of C-peptide cross-react with proinsulin, so that estimations of plasma C-peptide concentration may actually include a substantial quantity of proinsulin in diabetic patients with insulin antibcdies.P' The estimated plasma C-peptide concentration could therefore be increased spuriously unless antibodybound proinsulin is separated from C-peptide in plasrna.j" This technique has been used to investigate diabetic patients with residual beta-cell function who were suspected of inducing factitious hypoglycaemia with exogenous insulin, in whom plasma C-peptide was shown to be low after administration of insulin.51
ASSESSMENT OF PANCREATIC BETA-CELL FUNCTION C-peptide measurement in response to intravenous glucagon administration'" permits an assessment of residual pancreatic beta-cell function in patients with insulin-dependent diabetes. The latter has proved to be a valuable research tool, but at present its clinical application in the management of human diabetes is limited. It may be a useful method to demonstrate or assess the presence of adequate pancreatic beta-cell reserve in a few patients who are receiving unnecessary treatment with insulin. Plasma C-peptide may also be of use during the postoperative assessment of patients who have undergone pancreatectomy for carcinoma or nesidioblastosis. As these patients are usually insulindependent after surgical resection of the pancreas, plasma insulin levels per se cannot be interpreted, and the persistence of circulating C-peptide demonstrates the presence of residual functioning pancreatic islets. Similarly, in patients requiring insulin therapy after resection of an insulin-secreting tumour, abnormally elevated plasma C-peptide concentrations suggest the presence of functioning metastases or a recurrence of the original tumour. These potential uses of the C-peptide assay are infrequent in clinical practice.
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